GERON CORP Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity
GERON CORP (GERN) reported Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity of $23.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity · last filed 2021-11-09
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for the quarter ending 2021-09-30 was $23.00K, a 4.55% increase year-over-year.
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for the quarter ending 2021-06-30 was $23.00K, a 43.75% increase year-over-year.
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for the quarter ending 2021-03-31 was $25.00K, a 56.25% increase year-over-year.
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for the quarter ending 2020-09-30 was $22.00K, a 29.41% increase year-over-year.
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for fiscal 2020 was $85.00K, a 25.00% increase from fiscal 2019.
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for fiscal 2019 was $68.00K, a 64.40% decline from fiscal 2018.
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for fiscal 2018 was $191.00K, a 4.50% decline from fiscal 2017.
- GERON CORP share-based goods and nonemployee services transaction, stockholders' equity for fiscal 2017 was $200.00K, a 28.21% increase from fiscal 2016.
| Period end | Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity 3 month | Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity 6 month | Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity 9 month | Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity 12 month |
|---|---|---|---|---|
| 2021-09-30 | $23.00K 10-Q · filed 2021-11-09 | $46.00K derived: sum of 2 quarters · filed 2021-11-09 | $71.00K derived: sum of 3 quarters · filed 2021-11-09 | |
| 2021-06-30 | $23.00K 10-Q · filed 2021-11-09 | $48.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2021-03-31 | $25.00K 10-Q · filed 2021-11-09 | |||
| 2020-12-31 | $85.00K 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $22.00K 10-Q · filed 2021-11-09 | $38.00K derived: sum of 2 quarters · filed 2021-11-09 | $54.00K derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $16.00K 10-Q · filed 2021-11-09 | $32.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $16.00K 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $68.00K 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $17.00K 10-Q · filed 2020-11-05 | $28.00K derived: sum of 2 quarters · filed 2020-11-05 | $50.00K derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $11.00K 10-Q · filed 2020-11-05 | $33.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $22.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $191.00K 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $35.00K 10-Q · filed 2019-11-06 | $84.00K derived: sum of 2 quarters · filed 2019-11-06 | $155.00K derived: sum of 3 quarters · filed 2019-11-06 | |
| 2018-06-30 | $49.00K 10-Q · filed 2019-11-06 | $120.00K derived: sum of 2 quarters · filed 2019-11-06 | ||
| 2018-03-31 | $71.00K 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $200.00K 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $156.00K 10-K · filed 2019-03-07 | |||
| 2015-12-31 | $364.00K 10-K · filed 2018-03-16 | |||
| 2014-12-31 | $253.00K 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |